Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Vaccines|August 6, 2021
Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell ResponsesKirsi Tamminen, Suvi Heinimäki, Stina Gröhn, et al.
Viruses|January 26, 2019
Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 VariantKirsi Tamminen, Maria Malm, Timo Vesikari, et al.
Viral Immunology|February 27, 2013
Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotypeKirsi Tamminen, Leena Huhti, Timo Vesikari, et al.
The Journal of Infectious Diseases|June 28, 2014
High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in childrenMaria Malm, Hanni Uusi-Kerttula, Timo Vesikari, et al.
Scientific Reports|March 3, 2019
Development of T cell immunity to norovirus and rotavirus in children under five years of ageMaria Malm, Heikki Hyöty, Mikael Knip, et al.
Plos One|August 8, 2013
Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in miceKirsi Tamminen, Suvi Lappalainen, Leena Huhti, et al.
Virology|August 28, 2017
Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigensSuvi Heinimäki, Kirsi Tamminen, Maria Malm, et al.
Human Vaccines & Immunotherapeutics|October 16, 2015
Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccineVesna Blazevic, Maria Malm, Daisuke Arinobu, et al.
Vaccine|August 23, 2011
Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritisVesna Blazevic, Suvi Lappalainen, Kirsi Nurminen, et al.
Vaccine|December 17, 2017
Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypesMaria Malm, Kirsi Tamminen, Suvi Heinimäki, et al.
Pageof 6